1.Male or non-pregnant female adult â?¥ 18 years and â?¤ 60 Years of age at time of enrolment. <br/ >2.Patients diagnosed with mild COVID-19 (quarantine ward/home isolation). <br/ >3.Had initial onset of signs/symptoms attributable to COVID-19 for â?¤5 days prior to the day of randomization and at least 1 of the following sign/symptoms attributable to COVID-19 on the day of randomization. <br/ >uncomplicated upper respiratory tract infection, may have mild symptoms such as fever, cough, sore throat, nasal congestion, malaise, headache without any evidence of breathlessness <br/ >4.Patients with confirmed RT PCR positive reports <br/ >5.Female participants of childbearing potential must meet the following criteria to be enrolled: <br/ >i.Have a negative pregnancy test prior to randomization. <br/ >ii.Must agree to undergo a follow-up pregnancy test on study day 28. <br/ >Note that female not of childbearing potential is defined as either:Surgically sterile: Females who are permanently sterile via hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy by reported medical history and/or medical records. Surgical sterilization to have occurred a minimum of 6 weeks, or at â?¢ For female subjects: evidence of post-menopause, or for pre- menopause subjects, negative pre-treatment serum or urine pregnancy test and agree to take effective contraceptive measures (barrier methods or abstinence) with his /her partner during the study period and for at least 28 days following the last study treatment <br/ >6.Male participants with female partners must have either Surgical sterilization (vasectomy â?¥1 month before screening) OR <br/ >Female partner must be of not be of childbearing potential OR <br/ >Agree to take effective contraceptive measures (barrier methods or abstinence) with his /her partner during the study period and for at least 28 days following the last study treatment <br/ >7.Subjects who are ready to provide written informed consent and who are <br/ >ready to willingly participate and follow the IEC/IRB approved Informed Consent Form (ICF) prior to initiation of any study procedures <br/ > <br/ > <br/ >

1.Male or non-pregnant female adult â?¥ 18 years and â?¤ 60 Years of age at time of enrolment. <br/ >2.Patients diagnosed with mild COVID-19 (quarantine ward/home isolation). <br/ >3.Had initial onset of signs/symptoms attributable to COVID-19 for â?¤5 days prior to the day of randomization and at least 1 of the following sign/symptoms attributable to COVID-19 on the day of randomization. <br/ >uncomplicated upper respiratory tract infection, may have mild symptoms such as fever, cough, sore throat, nasal congestion, malaise, headache without any evidence of breathlessness <br/ >4.Patients with confirmed RT PCR positive reports <br/ >5.Female participants of childbearing potential must meet the following criteria to be enrolled: <br/ >i.Have a negative pregnancy test prior to randomization. <br/ >ii.Must agree to undergo a follow-up pregnancy test on study day 28. <br/ >Note that female not of childbearing potential is defined as either:Surgically sterile: Females who are permanently sterile via hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy by reported medical history and/or medical records. Surgical sterilization to have occurred a minimum of 6 weeks, or at â?¢ For female subjects: evidence of post-menopause, or for pre- menopause subjects, negative pre-treatment serum or urine pregnancy test and agree to take effective contraceptive measures (barrier methods or abstinence) with his /her partner during the study period and for at least 28 days following the last study treatment <br/ >6.Male participants with female partners must have either Surgical sterilization (vasectomy â?¥1 month before screening) OR <br/ >Female partner must be of not be of childbearing potential OR <br/ >Agree to take effective contraceptive measures (barrier methods or abstinence) with his /her partner during the study period and for at least 28 days following the last study treatment <br/ >7.Subjects who are ready to provide written informed consent and who are <br/ >ready to willingly participate and follow the IEC/IRB approved Informed Consent Form (ICF) prior to initiation of any study procedures <br/ > <br/ > <br/ >

1.Male or non-pregnant female adult â?¥ 18 years and â?¤ 60 Years of age at time of enrolment. <br/ >2.Patients diagnosed with mild COVID-19 (quarantine ward/home isolation). <br/ >3.Had initial onset of signs/symptoms attributable to COVID-19 for â?¤5 days prior to the day of randomization and at least 1 of the following sign/symptoms attributable to COVID-19 on the day of randomization. <br/ >uncomplicated upper respiratory tract infection, may have mild symptoms such as fever, cough, sore throat, nasal congestion, malaise, headache without any evidence of breathlessness <br/ >4.Patients with confirmed RT PCR positive reports <br/ >5.Female participants of childbearing potential must meet the following criteria to be enrolled: <br/ >i.Have a negative pregnancy test prior to randomization. <br/ >ii.Must agree to undergo a follow-up pregnancy test on study day 28. <br/ >Note that female not of childbearing potential is defined as either:Surgically sterile: Females who are permanently sterile via hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy by reported medical history and/or medical records. Surgical sterilization to have occurred a minimum of 6 weeks, or at â?¢ For female subjects: evidence of post-menopause, or for pre- menopause subjects, negative pre-treatment serum or urine pregnancy test and agree to take effective contraceptive measures (barrier methods or abstinence) with his /her partner during the study period and for at least 28 days following the last study treatment <br/ >6.Male participants with female partners must have either Surgical sterilization (vasectomy â?¥1 month before screening) OR <br/ >Female partner must be of not be of childbearing potential OR <br/ >Agree to take effective contraceptive measures (barrier methods or abstinence) with his /her partner during the study period and for at least 28 days following the last study treatment <br/ >7.Subjects who are ready to provide written informed consent and who are <br/ >ready to willingly participate and follow the IEC/IRB approved Informed Consent Form (ICF) prior to initiation of any study procedures <br/ > <br/ > <br/ >

1.Male or non-pregnant female adult â?¥ 18 years and â?¤ 60 Years of age at time of enrolment. <br/ >2.Patients diagnosed with mild COVID-19 (quarantine ward/home isolation). <br/ >3.Had initial onset of signs/symptoms attributable to COVID-19 for â?¤5 days prior to the day of randomization and at least 1 of the following sign/symptoms attributable to COVID-19 on the day of randomization. <br/ >uncomplicated upper respiratory tract infection, may have mild symptoms such as fever, cough, sore throat, nasal congestion, malaise, headache without any evidence of breathlessness <br/ >4.Patients with confirmed RT PCR positive reports <br/ >5.Female participants of childbearing potential must meet the following criteria to be enrolled: <br/ >i.Have a negative pregnancy test prior to randomization. <br/ >ii.Must agree to undergo a follow-up pregnancy test on study day 28. <br/ >Note that female not of childbearing potential is defined as either:Surgically sterile: Females who are permanently sterile via hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy by reported medical history and/or medical records. Surgical sterilization to have occurred a minimum of 6 weeks, or at â?¢ For female subjects: evidence of post-menopause, or for pre- menopause subjects, negative pre-treatment serum or urine pregnancy test and agree to take effective contraceptive measures (barrier methods or abstinence) with his /her partner during the study period and for at least 28 days following the last study treatment <br/ >6.Male participants with female partners must have either Surgical sterilization (vasectomy â?¥1 month before screening) OR <br/ >Female partner must be of not be of childbearing potential OR <br/ >Agree to take effective contraceptive measures (barrier methods or abstinence) with his /her partner during the study period and for at least 28 days following the last study treatment <br/ >7.Subjects who are ready to provide written informed consent and who are <br/ >ready to willingly participate and follow the IEC/IRB approved Informed Consent Form (ICF) prior to initiation of any study procedures <br/ > <br/ > <br/ >